Shanghai-based surgical-robot maker MicroPort MedBot (MEDBOT-B, 02252) has issued a circular convening its 2025 annual general meeting for 5 June 2026 in Shanghai. Key resolutions include:

1. Capital mandates • Issue Mandate – Directors may allot and issue up to 206.27 million additional shares, equivalent to 20% of the current 1.03 billion shares outstanding. • Buyback Mandate – Authority to repurchase up to 10% of issued capital, capped at 103.07 million H-shares and 60,974 domestic shares.

2. Profit distribution • No cash dividend or capitalisation issue for FY-2025 as the company recorded no distributable profit.

3. New equity-incentive plan • Adoption of a unified Share Scheme replacing the 2022 option and award plans. • Scheme Mandate Limit set at 10% of issued share capital (103.13 million shares) with a 2% sub-limit (20.63 million shares) for service-provider participants. • Minimum vesting period generally 12 months; exceptions allowed for “make-whole” grants, death, disability and other specified circumstances. • Scheme duration: 10 years from the adoption date, subject to shareholder approval.

4. Auditor re-appointment • KPMG (overseas) and KPMG Huazhen LLP (domestic) proposed as auditors for 2026; estimated audit fees range from RMB 2.70 million to RMB 3.00 million.

5. Meeting logistics • H-share register closes 2–5 June 2026; shareholders must lodge transfers by 4:30 p.m. on 1 June 2026 to qualify for voting rights.

All resolutions require shareholder approval at the AGM; voting will be conducted by poll.